Status:
RECRUITING
AI-Assisted Blood Glucose Management Study
Lead Sponsor:
Li Huating
Conditions:
Pre-diabetes
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
AI-driven health management tools can leverage continuous glucose monitoring (CGM), physical activity, and dietary data to provide real-time, individualized feedback, improving self-management and adh...
Eligibility Criteria
Inclusion
- Age 18-70 years
- Prediabetes (per ADA or WHO criteria)
- Stable lifestyle and body weight (±5%) for ≥3 months
- Owns and can operate a smartphone
- Able to understand and sign informed consent
Exclusion
- Current glucose-lowering medication use
- Severe cardiovascular disease, liver/kidney dysfunction, or active malignancy
- Psychiatric or cognitive disorders affecting participation
- Planned major surgery or long-distance travel during the study
- Allergy/intolerance to CGM sensor materials
Key Trial Info
Start Date :
September 7 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 26 2025
Estimated Enrollment :
123 Patients enrolled
Trial Details
Trial ID
NCT07160985
Start Date
September 7 2025
End Date
October 26 2025
Last Update
September 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Sixth People's Hospital
Shanghai, China